Publications by authors named "D P Stolz"
Purpose: Although studies have evaluated benralizumab, a monoclonal IL-5 receptor α antibody in severe eosinophilic asthma (SEA), in real-world settings, additional evidence is needed to further characterize its effectiveness in specific patient populations. Our study aimed to evaluate asthma control over 56 weeks in patients treated with benralizumab in Swiss real-world settings.
Patients And Methods: Conducted across 13 centres, this prospective, observational, non-interventional study involved 73 adults with physician confirmed SEA.
Background: Use of serum procalcitonin (PCT), an inflammatory biomarker for bacterial infections, has shown promising results for early stopping antibiotic treatment among patients with respiratory infections and sepsis. There is need for additional data regarding effectiveness and safety of this concept among patients with cancer.
Methods: Individual data of patients with a documented diagnosis of cancer and proven or suspected respiratory infection and/or sepsis were extracted from previous trials where adult patients were randomized to receive antibiotic treatment based on a PCT protocol or usual care (control group).
Article Synopsis
- Aspergillus species are linked to various conditions in bronchiectasis, including ABPA, AS, and increased IgG levels indicating exposure or infection.
- A study of nearly 10,000 bronchiectasis patients revealed 6.1% with ABPA, 5.7% with AS, and 8.1% with elevated Aspergillus-specific IgG levels, with these conditions associated with more severe lung issues and exacerbations.
- Long-term follow-up showed that those with raised IgG levels faced more frequent and severe exacerbations, particularly affecting patients not on inhaled corticosteroids.
Article Synopsis
- * Aspiration pneumonitis can lead to bacterial superinfections, and while antibiotics are necessary for pneumonia, supportive care is essential for pneumonitis; overlapping symptoms often lead to early antibiotic use.
- * Bronchoscopy is crucial for visualizing the airway, accessing biomarkers, and conducting invasive microbiological studies, which help tailor antibiotic treatments and minimize inappropriate use, especially in cases of foreign body aspiration.
Background: Lung transplantation (LTx) remains the only efficient treatment for selected patients with end-stage pulmonary disease. The age limit for the acceptance of donor organs in LTx is still a matter of debate. We here analyze the impact of donor organ age and the underlying pulmonary disease on short- and long-term outcome and survival after LTx.
View Article and Find Full Text PDF